louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01839760: Evaluation of Viral Shedding Patterns and Clinical Outcomes of Influenza Patients
Official title: Prospective Study to Evaluate Viral Shedding Patterns and Clinical Outcomes of Hospitalized Adult Influenza Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Influenza
Keywords: Influenza
Virus
Viral shedding
Epidemiology
Lead sponsor: Crucell Holland BV
Sponsor class: INDUSTRY
First posted: 2013-04-25
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hospitalized adult patients with laboratory-confirmed influenza A or B

Brief summary: The objective of the study is virological assessment (e.g., proportion of prolonged viral shedding, median days to viral clearance, and viral load) in laboratory-confirmed adult influenza patients admitted to the general ward and/or to the ICU and to assess the correlation with the clinical manifestations and prognosis.


Eligibility criteria: Inclusion Criteria:

* Written informed consent
* Hospitalized or admitted to ICU for influenza
* Age ≥18 years
* Laboratory confirmation of influenza A or B

Exclusion Criteria:

* Informed consent not given

Primary outcomes:
measure: Viral load/Viral shedding
timeFrame: Day 7
measure: Viral load/Viral shedding
timeFrame: Day 9
measure: Viral load/Viral shedding
timeFrame: Day 11
measure: Viral load/Viral shedding
timeFrame: Day 13
measure: Viral load/Viral shedding
timeFrame: Day 15
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Northwestern University
state: Illinois
city: Westmead
country: Australia
facility: Westmead Hospital
state: New South Wales
city: Adelaide
country: Australia
facility: Royal Adelaide Hospital
state: South Australia
city: Toronto
country: Canada
facility: North York General Hospital
state: Ontario
city: Toronto
country: Canada
facility: Mount Sinai Hospital
state: Ontario
Study officials:
References:
Clinical trial NCT03771560: Folinic Acid in Autism
Official title: An Examination of Changes in Urinary Metabolites With Use of Folinic Acid in Children With Autism Spectrum Disorder (ASD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Autism Spectrum Disorder
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
First posted: 2018-12-11
Enrollment: 18
Sex: ALL
Minimum age (years): 5
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: An examination of changes in urinary metabolites with use of folinic acid in children with autism spectrum disorder (ASD). Investigators will also measure behavioral measures and academic measures monthly at school with teachers and parents report.

Detailed description: Children enrolled in Oak Hill School will enroll in this study and take folinic acid supplement twice a day for 12 weeks period. Behavioral measures and urinary metabolites will be collected pre and post treatment. Behavioral measures will be taken again at 16 weeks, after 4 weeks of not dosing.

Eligibility criteria: Inclusion Criteria:

* Between ages 5 and 25

Exclusion Criteria:

* Not currently taking folinic acid

Primary outcomes:
measure: Aberrant Behavior Checklist (ABC) - Parent Reported Change
timeFrame: Baseline to Week 12
measure: Aberrant Behavior Checklist (ABC) - Teacher Reported Change
timeFrame: Baseline to Week 12
Secondary outcomes:
measure: Social Responsiveness Scale (SRS) - Parent Reported Change
timeFrame: Baseline to Week 12
measure: Social Responsiveness Scale (SRS) - Teacher Reported Change
timeFrame: Baseline to Week 12
measure: Pediatric Quality of Life (PedsQL) - Parent Reported Change
timeFrame: Baseline to Week 12
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California, San Francisco
state: California
Study officials:
affiliation: University of California, San Francisco
name: Robert Hendren, DO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06774560: Clinical Evaluation of 3D Printed Versus CAD/CAM Milled Onlays
Official title: Clinical Evaluation of 3D Printed Versus CAD/CAM Milled Onlays Over a Period of One Year: a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Badly Decayed Molars
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-01-14
Enrollment: 50
Sex: ALL
Minimum age (years): 25
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The digital workflow in dentistry has proven in the past decades to be a time-efficient, multifunctional, effortless, and accessible approach. The inherited shortages milling machines represented by the incapability to produce accurate complex hollow structures may give preference to modern 3D ceramic printing.

Computer-aided-design/computer-aided-manufacturing (CAD/CAM) in dentistry is a digital subtractive approach for manufacturing indirect restorations. Nevertheless, waste materials and milling burs wearing are considered as key disadvantages of CAD/CAM technology, and are the main drive to improve 3D printing technology (additive manufacturing) as the latter has shown considerable efficiency in minimising wasted materials.

Although additive manufacturing has been known since the 1980s, its application in dentistry is relatively new and not fully studied with limited research and in vivo studies on their clinical performance.


Eligibility criteria: Inclusion Criteria:

Age: 25-45 years.

* Males or females.
* Participants with carious vital ower molars indicated for onlay (one or two missing cusps)
* Patients with at least 20 teeth under occlusion.
* Good oral hygiene.
* Co-operative patients approving to participate in the trial.
* Have sufficient cognitive ability to understand consent procedures.

Exclusion Criteria:

* Participants with parafunctional habits or bruxism.
* Participants with systemic diseases or disabilities that may affect participation.
* Heavy smoking.
* Pregnancy.
* Lack of compliance.
* Severe or active periodontal disease.
* Cognitive impairment.

Primary outcomes:
measure: Fracture
timeFrame: One Year
Secondary outcomes:
measure: Retention
timeFrame: One Year
measure: Marginal adaptation
timeFrame: One Year
measure: Marginal discoloration
timeFrame: One Year
measure: Secondary caries
timeFrame: One Year
measure: Post-operative hypersensitivity
timeFrame: One Year
measure: Surface texture
timeFrame: One Year
measure: Anatomic form
timeFrame: One Year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00782860: Early Pregnancy Failure: Factors Affecting Successful Medical Termination Treatment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Early Pregnancy Failure
Keywords: Early pregnancy failure
Misoprostol
Gestational sac volume
Lead sponsor: Western Galilee Hospital-Nahariya
Sponsor class: OTHER_GOV
First posted: 2008-10-31
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women with missed abortion or anembryonic pregnancy, with existing intrauterine pregnancy sac

Brief summary: The main purpose of our study was to which determine factors, those measured by ultrasound and also demographic and clinical factors (age, number of previous pregnancies, abortions and deliveries) predict outcome of medical treatment for early pregnancy failure. Our hypothesis was that gestational sac volume predicts outcome of medical treatment for early pregnancy failure.


Eligibility criteria: Inclusion Criteria:

* Crown rump length (CRL) is appropriate to less than 12 weeks.

Primary outcomes:
measure: An empty uterus or an endometrial lining with thickness of less than 30mm.
Secondary outcomes:
Other outcomes:
Locations:
city: Nahariya
country: Israel
facility: Western Galilee Hospital-Nahariya
Study officials:
References:
Clinical trial NCT00687960: Effect of Resistant Starch Type 4 on Glycemia and Insulin Sensitivity in Young Adults
Official title: Effect of Resistant Starch Type 4 on Glycemia and Insulin Sensitivity in Young Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hyperglycemia
Keywords: Diabetes
Diet
Fiber
Age
Lead sponsor: Kansas State University
Sponsor class: OTHER
Collaborators: name: MGP Ingredients, Inc.
First posted: 2008-06-02
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study tested the effects of resistant starch type 4 on blood sugar and hunger in young adults with Type 2 diabetes.

Detailed description: To measure the blood glucose response, after an overnight fast, blood samples were collected before eating and at 15, 30, 45, 60, 90, and 120 minutes after each each bar. The incremental area under the curve was used to calculate the glycemic index and insulin sensitivity via minimal model.

Eligibility criteria: Inclusion Criteria:

* Apparently Healthy (not diagnosed with disease)
* Young Adults (18-35)

Exclusion Criteria:

* Diagnosed with diabetes or other metabolic disorders
* Allergies to Wheat
* Non-smokers

Primary outcomes:
measure: Post-Prandial Metabolism
timeFrame: Early morning
Secondary outcomes:
Other outcomes:
Locations:
city: Manhattan
country: United States
facility: Kansas State University
state: Kansas
Study officials:
affiliation: Department of Human Nutrition
name: Mark Haub, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01542060: Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus
Official title: A Clinical Experience Programme to Collect Data on the Safety and Efficacy of NovoMix® 30 in the Treatment of Patients With Type 2 Diabetes in Jordan
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes
Diabetes Mellitus, Type 2
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2012-03-01
Enrollment: 298
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients from hospitals or clinics diagnosed with type 2 diabetes mellitus

Brief summary: This study is conducted in Asia. The aim of this observational study is to collect efficacy and safety data of biphasic insulin aspart (NovoMix® 30) in type 2 diabetes under normal clinical practice conditions.


Eligibility criteria: Inclusion Criteria:

* Subjects from hospitals or clinics, diagnosed with type 2 diabetes mellitus

Primary outcomes:
measure: HbA1c (glycosylated haemoglobin)
Secondary outcomes:
measure: FBG (Fasting Blood Glucose)
measure: Quality of life assessed through the WHO-DTSQ (World Health Organization-Diabetes Treatment Satisfaction Questionnaire)
measure: Incidence of adverse events
measure: Incidence of hypoglycaemic episodes
Other outcomes:
Locations:
city: Amman
country: Jordan
Study officials:
affiliation: Novo Nordisk A/S
name: Corporate Vice President for diabetes and devices
role: STUDY_DIRECTOR
References:
Clinical trial NCT06150560: A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)
Official title: A Phase III, Randomized, Double-Blind, Placebo Controlled Clinical Trial Evaluating the Benefits and Mechanism Of Action Of Angiotensin-II Receptor Blocker On Cardiovascular Remodeling In Patients With Repaired Coarctation Of Aorta
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Coarctation of Aorta
High Blood Pressure
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2023-11-29
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to evaluate the effectiveness and mechanism of action of Losartan in the treatment of coarctation of aorta.


Eligibility criteria: Inclusion Criteria:

* B/S1 hypertension
* SBP 100-139 average based on 3 office measurements.
* Age 18 or Older
* Previous COA Repair

Exclusion Criteria:

* Currently on beta blocker (BB) therapy
* Pregnancy/lactating
* eGFR\<30
* Hyperkalemia (serum potassium \>5.5mmol/L)
* Severe Aortic or Mitral valve stenosis or regurgitation
* Epicardial CAD diagnosis
* Received antihypertensive medications within the past year

Primary outcomes:
measure: Change in Left Ventricular (LV) Fibrosis
timeFrame: Baseline; Week 52
Secondary outcomes:
measure: Change in Exercise Capacity (peak VO2)
timeFrame: Baseline; Week 52
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Alexander Egbe, MBBS, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05111860: Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy
Official title: Efficacy and Safety of Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy for RAS Mutant-type Locally Advanced Rectal Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Neoadjuvant Treatment
Rectal Cancer
Bevacizumab
Radiotherapy
Lead sponsor: Shanghai Minimally Invasive Surgery Center
Sponsor class: OTHER
First posted: 2021-11-08
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Prospectively Investigate the effectiveness and safety of neoadjuvant Bevacizumab + chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS mutant-type locally advanced rectal cancer


Eligibility criteria: Inclusion Criteria:

1. A biopsy proven histological diagnosis of rectal adenocarcinoma；
2. An ARMS-PCR proven KRAS, NRAS mutation, excluding BRAF mutation or microsatellite instablility-High;
3. No intestinal obstruction, distant metastasis was excluded by CT, MRI or PET / CT;
4. MRI proven T3c-T4, CRM positive, N2, extramural vascular invasion positive or lateral lymph node positive of locally advanced rectal cancer;
5. Age between 18-75 years;
6. ECOG (Eastern US Cooperative Oncology Group) score: 0-1;
7. Has sufficient organ function:

   * Hemopoietic function: hemoglobin ≥ 90 g / L, platelet ≥ 80 g / L × 109 / L,
   * neutrophils ≥ 1.5 × 109/L
   * Liver function: ALT and AST \< 2.5 × ULN;
   * Renal function: serum creatinine \< 1.5 ULN;
8. Willing to participate and informed consent signed；

Exclusion Criteria:

1. An ARMS-PCR proven RAS wild type, BRAF mutation and microsatellite instablility-High;
2. Patients having undergone chemotherapy, radiotherapy or surgery for colorectal cancer;
3. Patients with other uncontrolled malignant tumors (except early-stage basal cell carcinoma or cervical carcinoma in situ) ;
4. Female patients who are pregnant or breastfeeding;
5. Patients with severe heart, liver, or kidney, or neurological or psychiatric disease;
6. Patients with active infection;
7. Poor overall health status, ECOG ≥ 2;
8. Patients with concomitant diseases that seriously endanger the safety of patients or affect the completion of the study in the judgment of the investigator;
9. Known hypersensitivity reactions to any investigational drugs;

Primary outcomes:
measure: Peri-operative complications
timeFrame: From the start of treatment to 3 months after surgery
Secondary outcomes:
measure: Pathological response rate
timeFrame: 2 weeks after surgery
measure: Pathological complete response rate
timeFrame: 2 weeks after surgery
measure: 2-year local control rate
timeFrame: 2 years
measure: 2-year metastasis-free rate
timeFrame: 2 years
measure: Overall survival
timeFrame: 2 years
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Ruijin Hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT03328260: High Intensity Focused Ultrasound in Uterine Myoma
Official title: Prospective, Muti-institute, Single Arm, Confirmative Trial Evaluating Efficacy and Safety of High Intensity Focused Ultrasound Device (RODIN) in Women With Symptomatic Uterine Leiomyoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Uterine Leiomyoma
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
Collaborators: name: ALPINION Medical Systems
First posted: 2017-11-01
Enrollment: 34
Sex: FEMALE
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Aim to evaluate the efficacy of safety of newly developed, high intensity focused ultrasound device in women with symptomatic uterine leiomyoma


Eligibility criteria: Inclusion Criteria:

* Premenopausal (FSH \< 40 IU/L)
* Symptomatic uterine fibroids
* Willing to contracept during study period

Exclusion Criteria:

* Pregnant or willing to be pregnant in future
* Cancer in female reproductive organ is suspected or diagnosed
* Inflammation in female reproductive organ
* Poorly controlled systemic disease
* Hematocrit \< 25%
* Glomerular filtration rate(GFR) \<= 30ml/min
* Cannot tolerate contrast-enhanced MR or Contrast-enhanced ultrasound(CEUS)
* Cannot lie down
* Previous treatment for leiomyoma, any of ① myolysis, ② myomectomy within 1 year, ③ hormonal therapy longer than 7 days within 4 weeks
* Cannot count the number or measure volume of leiomyoma using MRI
* Leiomyomas are inadequate (location, volume, number) for intervention
* Diameter of leiomyoma is over 5 cm
* Leiomyoma is not enhanced
* Lactating women
* Cannot communicate properly
* Participating or have participated in other trials within 30 days

Primary outcomes:
measure: Non perfused volume
timeFrame: treatment day
Secondary outcomes:
Other outcomes:
Locations:
city: Seongnam Si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyenggi DO
Study officials:
References:
citation: Lee JY, Kim K, Hwang SI, Lee M, Son K, Kim D, Kim S, Kim YB. Efficacy and safety of transvaginal high-intensity focused ultrasound therapy in women with symptomatic uterine leiomyomas: A clinical trial. Eur J Obstet Gynecol Reprod Biol. 2021 Jan;256:302-307. doi: 10.1016/j.ejogrb.2020.11.049. Epub 2020 Nov 17.
Clinical trial NCT02422160: Vision Outcomes Using Quantitative Optical Coherence Tomography Evaluation in Age Related Macular Degeneration
Official title: Vision Outcomes Using Quantitative Optical Coherence Tomography Evaluation in Age Related Macular Degeneration
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Age-Related Macular Degeneration
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2015-04-21
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with non-exudative age-related macular degneration

Brief summary: The investigators have developed an image analysis method that can predict the likelihood that a patient with age related macular degeneration (AMD) will progress within 1 year, based on computerized analysis of optical coherence tomography (OCT) images that are routinely acquired in clinical practice on each patient visit to the ophthalmologist. The investigators' goal is to evaluate whether this method will improve the ability to detect AMD earlier and improve visual outcomes in AMD patients by assigning patient risk categories and having patients come back for follow up based on those categories.


Eligibility criteria: Inclusion Criteria:

* Non-exudative age-related macular degeneration

Exclusion Criteria:

* Exudative age-related macular degeneration

Primary outcomes:
measure: Visual Acuity
timeFrame: Two Years
Secondary outcomes:
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Byers Eye Institute at Stanford
state: California
Study officials:
References:
Clinical trial NCT04056260: ICG-NIR Guided Lymph Node Dissection in Gastric Cancer
Official title: Oncologic Safety of Sentinel Lymph Node-guided Lymph Node Dissection Using ICG-NIR Laparoscopy in Gastric Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Stomach Neoplasm
Lead sponsor: Seoul St. Mary's Hospital
Sponsor class: OTHER
First posted: 2019-08-14
Enrollment: 219
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: As the survival rate of patients with gastric cancer has increased, there has been a growing interest in interventions that improve postoperative quality of life. Therefore minimally invasive surgery or endoscopic resection has been performed much more frequently. However, adequate lymph node dissection is important as well. The aim of the study is to identify the feasibility of indocyanine green - near infra-red (ICG-NIR) guided sentinel lymph node dissection for the treatment of gastric cancer.


Eligibility criteria: Inclusion Criteria:

* dignosed gastric adenocarcinoma
* tumor: size 4cm or smaller
* depth of invasion: mucosa, submucosa, proper muscle
* candidates of laparoscopic radical gastrectomy
* informed consent

Exclusion Criteria:

* metachronous malignancy
* number of tumors: 2 or more
* remnant gastric cancer
* indication for endoscopic resection
* history of chemotherapy or radiation therapy
* pregnancy
* allergy to ICG
* metastatic gastric cancer

Primary outcomes:
measure: sensitivity and specificity
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: